Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (1871)	2/13/2002 7:27:33 PM
From: tom pope	Read Replies (1) \| Respond to of 3202

The take from Briefing, not good in the revenue shortfall(revenue shortfalls seem to be a kiss of death, and the AH is not happy): INCY Incyte Genomics tops estimates; guides lower on revenues (14.98 -0.27) Reports Q4 (Dec) loss of $0.22 per share, $0.04 better than the Multex consensus of ($0.26); revenues fell 1.1% year/year to $54.8 mln vs the $52.2 mln consensus; sees FY02 revenues in the range of $130-$150 mln versus the current consensus estimate for revenues of $205.8 mln.